Study of the effectiveness of IFN-beta monotherapy for hemodialysis patients with chronic hepatitis C

Study of the effectiveness of IFN-beta monotherapy for hemodialysis patients with chronic hepatitis C - Study of the effectiveness of IFN-beta monotherapy for hemodialysis patients with chronic hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011331

Enrollment

Registered

2013-07-31

Start date

2012-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 20 years of age or older Patients with HCV-RNA-positive that underwent hemodialysis And with or without liver biopsy Patients who consented to participate in the study

Exclusion criteria

Exclusion criteria: Patients with a history of hypersensitivity to against bovine-derived material and IFN preparation Patients with chronic liver disease other autoimmune hepatitis, and alcoholic liver injury Patients with liver failure and cirrhosis Patients with abnormal thyroid function Patients receiving in the Sho-saiko Patient patient that may be pregnant or are pregnant, breast-feeding Patients with severe depression Patients with a history of hypersensitivity to any vaccine, such as biological products Other patients who tested physician has determined is inappropriate participate in this study

Design outcomes

Primary

Measure	Time frame
HCV-RNA negative rate of 24 weeks after the end of treatment (SVR)	—

Countries

Japan

Contacts

Public ContactSawako Uchida

Osaka City University Graduate School of Medicine Department of Hepatology

sawako@med.osaka-cu.ac.jp06-6645-3905

Outcome results